The present invention provides methods and formulations for optimizing the anti-cancer and anti-HIV activities of a camptothecin drug including camptothecin and its related analogs including 9-aminocamptothecin and 9-nitrocamptothecin. The invention involves methodologies and formulations that limit human serum albumin-mediated reduction of the anti-cancer and anti-HIV effects of the camptothecins and the methods and formulations provide combination therapies in which binding of the camptothecin...

The use of fibrates, particularly clofibrate, is described for the preparation of a medicament useful in the treatment of congestive heart failure.

The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monens...

The present invention relates to methods for enhancing Hypoxia inducible factor- 1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monen...

Provided is an antagonist of LXR activity for use as a medicament for use in the prevention, reduction or inhibition of scarring. Corresponding methods of treatment are also provided. It is preferred that the scarring to be inhibited is scarring associated with wound healing. Preferred antagonists of LXR activity include fibrate esters (such as fenofibrate ester